CVR: 37988936
Endothel Pharma ApS is a Danish company of the type Anpartsselskab based in København K, founded in 2016. The company is registered under the industry Fremstilling af farmaceutiske præparater. The management consists of Rikke Stine Friis Fléron. The company is owned by Bo Jesper Hansen, Pär Ingemar Johansson and Trial-Lab Holding AB. In 2025, the company reported a gross profit of DKK -43,536 and a net result of DKK -87,006 compared with DKK -81,618 the year before. Equity amounted to DKK -462,946.
Your company? Claim the profile and show your logo, website and social channels — for free.
Claim this profileSelskabets formål er at udvikle lægemidler samt dermed beslægtet virksomhed
Build lead lists with filters on industry, geography, size and financials — and export straight to Excel.
Try the lead list generatorCompared to 129 companies in Fremstilling af farmaceutiske præparater
Comparison is based on industry median values
Screen owners and management against the Danish FSA's official PEP lists
Contact info changed: new email: [email protected] (April 2, 2026).
As of April 1, 2026, Rikke Stine Friis Fléron is registered as director of Endothel Pharma ApS.
As of March 31, 2026, Sisse Rye Ostrowski has stepped down as director of Endothel Pharma ApS.
Contact info changed: new email: [email protected] (March 27, 2026).
As of February 17, 2026, Bo Jesper Hansen is registered as an owner of Endothel Pharma ApS with an ownership share of 50%.
As of February 17, 2026, is registered as an owner of Endothel Pharma ApS with an ownership share of 50%.
As of February 17, 2026, is registered as an owner of Endothel Pharma ApS with an ownership share of 50%.
Endothel Pharma ApS has published its annual report for 2025. Gross profit came to DKK -43,536, and the net result was DKK -87,006.
Endothel Pharma ApS has published its annual report for 2024. Gross profit came to DKK -42,292, and the net result was DKK -81,618.
Endothel Pharma ApS has published its annual report for 2023. Gross profit came to DKK -57,141, and the net result was DKK -91,000.
Endothel Pharma ApS has published its annual report for 2022. Gross profit came to DKK -47,868, and the net result was DKK -76,253.
Endothel Pharma ApS has published its annual report for 2021. Gross profit came to DKK -25,128, and the net result was DKK -46,607.
Endothel Pharma ApS has published its annual report for 2020. Gross profit came to DKK -12,618, and the net result was DKK -28,925.
Endothel Pharma ApS has published its annual report for 2019. Gross profit came to DKK -23,142, and the net result was DKK -36,111.
Endothel Pharma ApS has published its annual report for 2018. Gross profit came to DKK -52,984, and the net result was DKK -59,310.
Endothel Pharma ApS has published its interim report for the period August 31, 2016 – December 31, 2017.
As of April 10, 2017, Leif Helth Jensen has left the board of directors of Endothel Pharma ApS.
As of April 10, 2017, Sisse Rye Ostrowski has left the board of directors of Endothel Pharma ApS.
As of April 10, 2017, Pär Ingemar Johansson has left the board of directors of Endothel Pharma ApS.
As of April 10, 2017, Sisse Rye Ostrowski is registered as director of Endothel Pharma ApS.
As of April 10, 2017, Leif Helth Jensen has stepped down as director of Endothel Pharma ApS.
As of August 31, 2016, Leif Helth Jensen has joined the board of directors of Endothel Pharma ApS.
As of August 31, 2016, Sisse Rye Ostrowski has joined the board of directors of Endothel Pharma ApS.
As of August 31, 2016, Pär Ingemar Johansson has joined the board of directors of Endothel Pharma ApS.
As of August 31, 2016, Leif Helth Jensen is registered as director of Endothel Pharma ApS.
Endothel Pharma ApS was founded on August 31, 2016.
Companies in the same industry and area
CVR 45984842
CVR 34668272
CVR 45663205
CVR 44714922
CVR 33871902
companydata.dk